OTCMKTS:INTI Inhibitor Therapeutics (INTI) Stock Price, News & Analysis $0.07 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.07▼$0.0750-Day Range$0.05▼$0.0952-Week Range$0.03▼$0.30VolumeN/AAverage Volume17,381 shsMarket Capitalization$11.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Inhibitor Therapeutics alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Inhibitor Therapeutics Stock (OTCMKTS:INTI)Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.Read More INTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INTI Stock News HeadlinesAugust 31, 2024 | uk.investing.comInternational Industries Ltd (INTI)August 22, 2024 | globenewswire.comInhibitor Therapeutics, Inc. Provides Update on its Clinical Development PlanSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 15, 2024 | finance.yahoo.comJanus Kinase (JAK) Inhibitor Therapeutic Report 2024: Strategic Evaluation of Over 50 Companies and 55+ Pipeline DrugsAugust 15, 2024 | seekingalpha.comInhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | markets.businessinsider.comOncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsJuly 30, 2024 | msn.comNew dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistanceJuly 25, 2024 | benzinga.comPreview: Actuate Therapeutics, Inc Set To IPO TomorrowSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 24, 2024 | benzinga.comActuate Therapeutics, Inc IPOs Tomorrow, Here's What You Need To KnowMay 29, 2024 | seekingalpha.comActuate Therapeutics Seeks IPO For Promising Pancreatic Cancer DrugsMay 23, 2024 | businesswire.comNimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual MeetingMay 13, 2024 | tmcnet.comMC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion StrategyApril 30, 2024 | seekingalpha.comGTHX G1 Therapeutics, Inc.April 24, 2024 | finance.yahoo.comHDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsightApril 22, 2024 | finance.yahoo.comEGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsightApril 15, 2024 | finance.yahoo.comCyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth ProspectsApril 8, 2024 | msn.comSaruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialSee More Headlines Receive INTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:INTI CUSIPN/A CIK1042418 Webwww.inhibitortx.com Phone(888) 841-6811Fax813-527-0500Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.88% Return on Assets-36.02% Debt Debt-to-Equity RatioN/A Current Ratio201.90 Quick Ratio201.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book3.45Miscellaneous Outstanding Shares172,268,000Free Float164,344,000Market Cap$11.88 million OptionableNot Optionable Beta-0.64 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Francis E. O'Donnell Jr. (Age 74)M.D., Founder, Executive Chairman & CEO Comp: $600kMr. James A. McNulty CPA (Age 74)Interim CFO, Treasurer & Secretary Comp: $205.4kKey CompetitorsBioLineRxNASDAQ:BLRXReneo PharmaceuticalsNASDAQ:RPHMProPhase LabsNASDAQ:PRPHCalciMedicaNASDAQ:CALCZIVO BioscienceNASDAQ:ZIVOView All Competitors INTI Stock Analysis - Frequently Asked Questions How have INTI shares performed this year? Inhibitor Therapeutics' stock was trading at $0.0920 at the start of the year. Since then, INTI shares have decreased by 25.0% and is now trading at $0.0690. View the best growth stocks for 2024 here. How do I buy shares of Inhibitor Therapeutics? Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:INTI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.